EP1039919A1 - Composition for improving mental capabilities in mammals - Google Patents

Composition for improving mental capabilities in mammals

Info

Publication number
EP1039919A1
EP1039919A1 EP99940453A EP99940453A EP1039919A1 EP 1039919 A1 EP1039919 A1 EP 1039919A1 EP 99940453 A EP99940453 A EP 99940453A EP 99940453 A EP99940453 A EP 99940453A EP 1039919 A1 EP1039919 A1 EP 1039919A1
Authority
EP
European Patent Office
Prior art keywords
agents
composition
extract
becoppa
monnieri
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99940453A
Other languages
German (de)
French (fr)
Inventor
Maharaj Krishen Pandita
Govind Prashad Dubey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MURALI, PANCHAPAGESA MUTHUSWAMY, DR.
Original Assignee
Maharaj Krishen Pandita
Govind Prashad Dubey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IN146DE1999 external-priority patent/IN191484B/en
Priority claimed from IN220DE1999 external-priority patent/IN191695B/en
Application filed by Maharaj Krishen Pandita, Govind Prashad Dubey filed Critical Maharaj Krishen Pandita
Publication of EP1039919A1 publication Critical patent/EP1039919A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/882—Acoraceae (Calamus family), e.g. sweetflag or Acorus calamus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • This invention relates to a composition for improving mental capabilities in children, adults and mentally deficient people.
  • the composition of the present invention is advantageously used for improving short term memory, long term memory and attention span, by exerting its effect on increasing concentration ability, increasing short term and long term memory span, improving learning ability, speech & recall defects and improving overall mental performance.
  • Brahmi herb has memory enhancement activity.
  • Brahmi Herb refers to an herbal composition consisting of the whole plants, plant parts, or extracts of Becoppa monnieri and/ or Centella asiaticia, both of which can be found growing in wet climates throughout the tropical zones of India. Highest yield was found in valley of Brahmaputra, Assam and West Bengal. It is also known that Becoppa monnieri / Centella asiatica can be processed to obtain either a hydro, hydro-alcoholic or alcoholic extract, and that the herb itself or any of the above extracts may be used for memory enhancement.
  • Herb and herbal extracts of Acorus calamus are also known in the art for memory enhancement.
  • such extracts known in the art contain ⁇ - asarone present in an amount of about 500-700 ppm.
  • a disadvantage associated with the known Acorus calamus is the presence of ⁇ -asarone, which has carcinogenic properties.
  • Acorus calamus is found in Jerusalem, Punjab, Himachal Pradesh and Madhya Pradesh.
  • Extract of Celestrus paniculatus oil is used for reduction in hyper activity of the brain thus permits the nerves to retain the information process for improving the memory.
  • Memory is a complex process regulated by various factors viz. anxiety, reaction, derangement of neuron transmitters, particularly acetylecheline including seroyrotimine are responsible of the regulation of memory. Malnutrition, particularly, iodine deficiency, protein deficiency also play a significant role in memory regulation.
  • the object of this invention is therefore, to propose a highly potent composition for improving overall mental performance i.e. long term memory, short term memory, attention span, its retention, recall and speech defects by arresting the loss of acstylcholine, increasing capabilities of neurons to retain information, decreasing the hyperexcitability of nervous system in the brain by reducing catecholiamine level, reducing emotional fluctuation by regulating 5 HT in the brain.
  • the second object of this invention is to prevent the presence of ⁇ - asarone, in quantities of > 5 ppm in Acorus calamus, which makes the composition safer and free from side effects.
  • this invention provides a highly potent herbal composition for improving overall mental performance in children, adults and mentally deficient people characterized by using extracted active plant materials from Brahmi herb and at least one of the herbs from Acorus calamus and Celestrus paniculatus oil.
  • the said highly potent herbal composition for improving overall mental performance in children, adults and mentally deficient people in 10ml/ 1 lgms characterized by using extracted active plant materials from Brahmi herb and at least one of the herbs from Acorus calamus and Celestrus paniculatus oil in the amounts as given below:
  • Celestrus paniculatus oil - about 0.02-0.2 ml and the balance amount, if any, is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
  • This composition will have excellent properties of improving the overall mental performance, for instance, a child having lower memory due to higher level of anxiety and aggressiveness, the Centella asiatica in the composition will decrease serotonine and thereby reduce the anxiety and Celestrus paniculatus oil in the composition will decrease the catecholiamine and thereby reduces the aggressiveness and simultaneously making the other components of the composition active and improve the overall mental performance.
  • the herbal extracts are in the form of a powder, liquid or paste and the quantities used are based on dry powder as given in the composition.
  • Brahmi herb extract is either obtained from Becoppa monnieri or from Centella asiatica or from combination of both.
  • the preferred range of the following herbal material is as follows:
  • Centella asiatica about 25-200 mg
  • the Becoppa monnieri and Centella asiatica used in the composition has preferably saponins content about 15-25%.
  • the Acorus calamus used has preferably about 40-55% glycosides and ⁇ -asarone content below 5 ppm.
  • Becoppa monnieri extract and Centella asiatica are hydro-alcoholic organic extracts.
  • the said Acorus calamus extract is hydro-alcoholic extract of the Rhizone of the herb and the extraction technique is adopted to either eliminate the ⁇ -asarone for obtaining extract of Acorus calamus or with ⁇ -asarone less than 5 ppm and the contents of ⁇ -asarone in the extract is measured by gas chromatography recommended by FDA, USA
  • the extract of Celestrus paniculatus oil is an oil extract.
  • the extract of Becoppa monnieri for use in the composition is either prepared by any known process or by refluxing an alcoholic extract of Becoppa monnieri, concentrating to a solid content of about 50-70% and drying the refluxed material at temperature about 50-90°C under vacuum, treating the dried material with organic solvent preferably chloroform for removal of the soluble fraction and then subjecting the insoluble fraction to refining to obtain a debitterized rich fraction of glycosides.
  • the said composition is in a powder, tablet, capsule, syrup or in suspension form and also is delivered through any other known carriers such as biscuits/snacks.
  • Celestrus paniculatus oil is first adsorbed in Aerosil or any other suitable known adsorbing media and used accordingly.
  • the Nootropic components present in the composition improves short term memory, long term memory and attention span, by exerting its effect on increasing concentration ability, increasing memory span, improving learning ability and overall mental performance.
  • the activity of each of such constituents when present in combination has been ascertained and tests have shown that better levels of enhancement of memory facets are obtained where both the constituents are present in the composition.
  • the nootropic & psychotropic properties are achieved.
  • the composition includes only Becoppa monnieri.
  • the composition contains both Becoppa monnieri and Centella asiatica.
  • the extract of Shatparvika comprises Acorus calamus and should have glycosides present in the range of about 35 to 65%. Preferably, but without implying any limitation to the scope of the invention, about 40-55% of glycosides is present in the Acorus calamus. Further, ⁇ -asarone present in Acorus calamus should not exceed to more than 5 ppm. Acorus calamus is responsible for recall and expression of the stored information from the brain.
  • the extract is hydro-alcoholic extract of the Rhizome of the herb Acorus calamus and the extraction technique is adopted to either eliminate the ⁇ - asarone for obtaining extract of Acorus calamus or with ⁇ -asarone ⁇ 5 ppm.
  • the extract of Vadangul used in the present invention comprises
  • the composition contains about 100-500 mg of Becoppa monnieri and preferably between 150- 300 mg. If less than 150 mg is present the efficacy of the composition is adversely affected, and desired results can not be obtained. If the composition contains more than 300 mg no additional activity is achieved. In fact, if the composition contains excessively high amount of Becoppa monnieri, such as more than 2000 mg the gastric irritation has been observed.
  • Centella asiatica is present.
  • the composition contains about 25-200 mg of Centella asiatica.
  • Such a composition also contains about 7.5 - 25 mg of Acorus calamus and preferably about 8.0 to 20 mg.
  • the composition contains about 0.02 to 0.20 ml and preferably about 0.04 to 0.15 ml of Celestrus paniculatus oil.
  • the composition may be in a powder, tablet, capsule, syrup or suspension form.
  • an alcoholic or hydro-alcoholic extract of Becoppa monnieri prepared by the process of the present invention and as described subsequently herein is employed in the composition, as the bitter constituents are removed therefrom.
  • a particular and advantageous . application is with respect to a syrup form, as a bitter palatable taste ought to be avoided.
  • the hydro-alcoholic extract of Becoppa monnieri of the process of the present invention is used in the composition.
  • the starting material comprises an alcoholic extract of Becoppa monnieri and Centella asiatica, which is refluxed till the herb is exhausted and so as to obtain an extract having glycosides and other compounds certain of which are bitter and undesirable constituents.
  • the refluxed material is concentrated to have a solid content of about 50-70% under vacuum conditions and that the operating temperature is between 50-70°C.
  • the concentrated product is dried at a temperature of about 50-90°C. It has been found that if higher temperature is employed it would then destroy or change the nature of palatable and active glycosides contained in the extract.
  • the step of drying may be effected in a drum or tray dryer under vacuum at a temperature of about 50 to 90°C,and preferably about 50- 70°C so as to prevent any thermal damage to the palatable glycosides and to obtain a powdered form of the extract.
  • the step of spraying drying may be effected in a spray dryer.
  • the step of drying is carried out for a period of about 40 to 120 sees and preferably for a period of about 60 to 80 sec. If the step of drying is effected in a tray or drum dryer, the step of milling them follows the step of drying. In the instance of spray drying, the operating temperature should preferably be between 70 to 80°C.
  • the dried extract is subjected to the step of solubilising in solvents namely chloroform.
  • the extracts are soluble in other solvents rather than chloroform, which are preferably not employed, as certain of the bitter constituents present in the extract are also soluble in such other solvents.
  • the step of solubilising is preferably carried out in chloroform as a solvent under atmospheric condition to obtain a soluble fraction and an insoluble fraction.
  • the soluble fraction is rejected and such a process may be repeated for refinement of the insoluble fraction.
  • the insoluble fraction is filtered and concentrated at about 50-70°C under vacuum and then dried also at a temperature not exceeding 70°C.
  • the dried powder is subjected to the step of refinement, which comprises in a first step of dissolving the said powder in water to obtain a soluble fraction.
  • the soluble fraction is filtered and concentrated to about 50- 70% solids under vacuum.
  • the step of refining consists in a second step and wherein the concentrated solids obtained from the first step of refining is dissolved in alcohol to obtain an alcohol soluble fraction and a second insoluble fraction.
  • the alcohol soluble fraction is concentrated under vacuum at a temperature of about 50-70°C to obtain a concentrated powder to about 50-70% solid of content.
  • the step of refinement comprises in a third step, wherein the alcohol soluble fraction is dissolved in acetone to obtain a first fraction containing acetone soluble material and a second fraction insoluble in acetone and comprising debitterized glycocidic rich fraction, which is also subjected to the step of concentration and then finally dried at a temperature of about 50 to 70°C.
  • the step of drying may be effected after each step of refinement or only after the third step of refinement.
  • a 10 ml composition in the form of syrup contained the following active ingredients: about 120 mg of the alcoholic extract of Becoppa monnieri about 15 mg of extract of Centella asiatica, about 15 mg of ⁇ -asarone free extract of Acorus calamus, about 0.03 ml of extracted oil of Celestrus paniculatus oil and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
  • Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor.
  • a 10 ml composition in the form of syrup contained the following active ingredients: about 250 mg of the alcoholic extract of Becoppa monnieri about 40 mg of extract of Centella asiatica, - about 22 mg of ⁇ -asarone free extract of Acorus calamus, about 0.15 ml of extracted oil of Celestrus paniculatus oil and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
  • a 10 ml composition in the form of syrup contained the following active ingredients: - about 250 mg of the alcoholic extract of Becoppa monnieri about 40 mg of extract of Centella asiatica, about 22 mg of ⁇ -asarone free extract of Acorus calamus, and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
  • active ingredients - about 250 mg of the alcoholic extract of Becoppa monnieri about 40 mg of extract of Centella asiatica, about 22 mg of ⁇ -asarone free extract of Acorus calamus, and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
  • Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor.
  • a 10 ml composition in the form of syrup contained the following active ingredients: - about 200 mg of the alcoholic extract of Becoppa monnieri about 25 mg of ⁇ -asarone free extract of Acorus calamus, about 0.10 ml of extracted oil of Celestrus paniculatus oil and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
  • Dosage Children upto 5 years about 5 ml - two times a day
  • Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor.
  • composition II exhibited marked improvement in nootropic properties. However, the degree of improvement was lesser than composition II. In the absence of Centella asiatica no psychotropic activity could be identified.
  • composition was beneficial for short term, long term and improvement in the attention span.
  • degree of significance noted was p ⁇ 0.02.
  • a 10 ml composition in the form of syrup contained the following active ingredients: about 200 mg of the alcoholic extract of Becoppa monnieri . - about 25 mg of ⁇ -asarone free extract of Acorus calamus, and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents. Dosage: Children upto 5 years about 5 ml - two times a day
  • compositions can be increased depending upon the severity of the disease or as prescribed by the doctor.
  • the composition exhibited marked improvement in nootropic properties. However, the degree of improvement was lesser than composition II. In the absence of Centella asiatica no psychotropic activity could be identified. However, the composition was beneficial for short term, long term and improvement in the attention span.
  • a 10 ml composition in the form of syrup contained the following active ingredients: about 200 mg of extract of Centella asiatica, about 25 mg of ⁇ -asarone free extract of Acorus calamus, - about 0.10 ml of extracted oil of Celestrus paniculatus oil and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
  • Dosage Children upto 5 years about 5 ml - two times a day
  • Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor.
  • composition in the form of syrup contained the following active ingredients: about 200 mg of the alcoholic extract of Centella asiatica - about 25 mg of ⁇ -asarone free extract of Acorus calamus and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
  • active ingredients about 200 mg of the alcoholic extract of Centella asiatica - about 25 mg of ⁇ -asarone free extract of Acorus calamus and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
  • Dosage Children upto 5 years about 5 ml - two times a day
  • EXAMPLE VDT 10 ml composition in the form of syrup contained the following active ingredients: about 200 mg of the alcoholic extract of Becoppa monnieri about 40 mg of extract of Centella asiatica, about 0.10 ml of extracted oil of Celestrus paniculatus oil and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
  • Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor.
  • a 10 ml composition in the form of syrup contained the following active ingredients: about 200 mg of the alcoholic extract of Becoppa monnieri about 0.15 ml of extracted oil of Celestrus peniculatus and the balance amount is from known additives selected from stabilizers, a ⁇ ti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents. Dosage:
  • Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor.
  • a 10 ml composition in the form of syrup contained the following active ingredients: about 200 mg of extract of Centella asiatica, about 0.15 ml of extracted oil of Celestrus peniculatus and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
  • Dosage Children upto 5 years about 5 ml - two times a day
  • Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor.
  • the brahmi herb (Becoppa monnieri / Centella asiatica) as a complete plant was dried and extracted with absolute Ethanol in a Stainless Steel Pan. Four parts of Ethanol was mixed with one part of Herb and the material refluxed for about 10-12 hours. The process was repeated about 6 times till the herb is exhausted. All the above 6 extractions were concentrated to a paste of about 80% solids. This was done under vacuum and the solvents were recovered. The material was dried under reduced pressure at a temperature of about 50°C in a vacuum drum drier. The powder obtained was extracted with pure chloroform (6 times) to remove the alkalides and oils. Identity test for alkaloids was performed. The material was filtered and chloroform insoluble fraction was concentrated to about 70% solids.
  • the residue was dried in a vacuum drum drier.
  • the dried powder was dissolved in about 6 times the quantity of distilled water and filtered.
  • the supernatant was reduced to about 80% solids under vacuum and dissolved in pure Ethyl alcohol.
  • the alcohol soluble fraction was reduced to about 80% solids under vacuum and dissolved in about 4 times the quantity of acetone.
  • the acetone insoluble fraction was dried in drum drier.
  • the dried powder was glycocidal rich fraction and debitterized extract of Brahmi herb. Identity test and quantitative analysis of saponins (Tritrepenic glycocides) was conducted. This fraction had saponin content of above about 15% to 20%.
  • Celestrus paniculatus oil is first adsorbed in Aerosil or any other suitable known adsorbing media and used accordingly.
  • composition is in the form of biscuits or snacks, each unit should contain the active ingredients as specified in the aforesaid examples.
  • composition described and claimed is based on the herbal extracts in powder form and in the case Celestrus paniculatis in oil form. However, if the composition is made in liquid form, the extract described can also be used in paste / liquid form and the quantities calculated on the dry matter content corresponding to above composition.
  • Celestrus paniculatus oil is brought into water soluble phase by using Tween-20 or any such known emulsifying agent.
  • composition described above is useful for treating the diseases which cause the mental incapabilities such as lower cholinergic activity, lower level of protein synthesis, presence of higher level of catechaliamine, improper functioning of 5 FIT in the brain, lower I.Q. level i.e. 70-50 and mental retardation caused by the following factors: - health of mother genetic disease; chromosomal diseases; maternal illness; anemia; - cardio-pulmonary diseases; hemorrhage and hypertension; malnutrition and the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a highly potent herbal composition for improving overall mental performance in children, adults and mentally deficient people characterized by using extracted active plant materials from Brahmi herb and at least one of the herbs from Acorus calamus and Celestrus paniculatus oil.

Description

TITLE OF THE INVENTION:
COMPOSITION FOR IMPROVING MENTAL CAPABILITIES IN MAMMALS FILED OF THE INVENTION:
This invention relates to a composition for improving mental capabilities in children, adults and mentally deficient people. In particular though not limited thereto, the composition of the present invention is advantageously used for improving short term memory, long term memory and attention span, by exerting its effect on increasing concentration ability, increasing short term and long term memory span, improving learning ability, speech & recall defects and improving overall mental performance. BACKGROUND
It is generally known that Brahmi herb has memory enhancement activity. Brahmi Herb, as used herein, refers to an herbal composition consisting of the whole plants, plant parts, or extracts of Becoppa monnieri and/ or Centella asiaticia, both of which can be found growing in wet climates throughout the tropical zones of India. Highest yield was found in valley of Brahmaputra, Assam and West Bengal. It is also known that Becoppa monnieri / Centella asiatica can be processed to obtain either a hydro, hydro-alcoholic or alcoholic extract, and that the herb itself or any of the above extracts may be used for memory enhancement. However, a disadvantage associated with the use of above extracts or the herb is that it contains a substantial quantity of bitter and other undesirable constituents producing negative effect like presence of alkaloids (inhibition of tissue respiration and alteration of blood pressure), sterols (suppresses the immune competence), raisins (alters mortality) and in case of herbs large quantities are required for achieving the benefits. The herbs also contain varying quantities of active principles depending on various parameters i.e. location, climate etc. Thus, not only making the dose administration impossible but also makes the evaluation of its therapeutic potential difficult. Extract of Centella asiatica are also known to be used for addressing memory enhancement by improving psychotropic potential.
Herb and herbal extracts of Acorus calamus are also known in the art for memory enhancement. However, such extracts known in the art contain β- asarone present in an amount of about 500-700 ppm. A disadvantage associated with the known Acorus calamus is the presence of β-asarone, which has carcinogenic properties. Acorus calamus is found in Kashmir, Punjab, Himachal Pradesh and Madhya Pradesh.
Extract of Celestrus paniculatus oil is used for reduction in hyper activity of the brain thus permits the nerves to retain the information process for improving the memory.
Memory is a complex process regulated by various factors viz. anxiety, reaction, derangement of neuron transmitters, particularly acetylecheline including seroyrotimine are responsible of the regulation of memory. Malnutrition, particularly, iodine deficiency, protein deficiency also play a significant role in memory regulation.
Upto this date, nobody has done any work on the combined effect of the above herbs, namely, Brahmi (Becoppa monnieri and Centella asiatica), Acorus calamus and Celestrus paniculatus oil, for improving overall mental performance.
Each of the above mentioned herbs upto now were used individually to increase the memory in general i.e. without any specific indications. No stud} was carried out ever or published to assess the mode of function of each of the above stated herbs. As a result, these were not having appropriate effect depending upon the lack of particular facet in a particular person whose memory is weak. For example, a child having lower memory due to higher level of anxiety, aggressiveness, Brahmi fails to have any noticeable effect on the memory of the child. Similarly, the properties of Acorus calamus are to increase the protein synthesis thus increases the capabilities of the neuron to retain / increase the information / retention span. The inventor is the first to establish conclusively that memory failure may not be treated, or enhanced appropriately by administering any single herb. As a result of these findings, this invention provides herbal compositions which can now be administered to successfully modulate memory failure due to a number of different causes.
The object of this invention is therefore, to propose a highly potent composition for improving overall mental performance i.e. long term memory, short term memory, attention span, its retention, recall and speech defects by arresting the loss of acstylcholine, increasing capabilities of neurons to retain information, decreasing the hyperexcitability of nervous system in the brain by reducing catecholiamine level, reducing emotional fluctuation by regulating 5 HT in the brain.
The second object of this invention is to prevent the presence of β- asarone, in quantities of > 5 ppm in Acorus calamus, which makes the composition safer and free from side effects.
THE INVENTION AND ITS DETAILED DESCRIPTION:
To achieve the said objectives this invention provides a highly potent herbal composition for improving overall mental performance in children, adults and mentally deficient people characterized by using extracted active plant materials from Brahmi herb and at least one of the herbs from Acorus calamus and Celestrus paniculatus oil.
The said highly potent herbal composition for improving overall mental performance in children, adults and mentally deficient people in 10ml/ 1 lgms characterized by using extracted active plant materials from Brahmi herb and at least one of the herbs from Acorus calamus and Celestrus paniculatus oil in the amounts as given below:
Brahmi herb - about 100-500 mg
Acorus calamus - about 7.5-35 mg
Celestrus paniculatus oil - about 0.02-0.2 ml and the balance amount, if any, is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
This composition will have excellent properties of improving the overall mental performance, for instance, a child having lower memory due to higher level of anxiety and aggressiveness, the Centella asiatica in the composition will decrease serotonine and thereby reduce the anxiety and Celestrus paniculatus oil in the composition will decrease the catecholiamine and thereby reduces the aggressiveness and simultaneously making the other components of the composition active and improve the overall mental performance.
The herbal extracts are in the form of a powder, liquid or paste and the quantities used are based on dry powder as given in the composition.
Brahmi herb extract is either obtained from Becoppa monnieri or from Centella asiatica or from combination of both.
The preferred range of the following herbal material is as follows:
Becoppa monnieri - about 150-300 mg
Centella asiatica - about 25-200 mg
Acorus calamus - about 8-20 mg Celestrus paniculatus oil - about 0.04-0.15 ml
The Becoppa monnieri and Centella asiatica used in the composition has preferably saponins content about 15-25%.
The Acorus calamus used has preferably about 40-55% glycosides and β-asarone content below 5 ppm. Becoppa monnieri extract and Centella asiatica are hydro-alcoholic organic extracts.
The said Acorus calamus extract is hydro-alcoholic extract of the Rhizone of the herb and the extraction technique is adopted to either eliminate the β-asarone for obtaining extract of Acorus calamus or with β-asarone less than 5 ppm and the contents of β-asarone in the extract is measured by gas chromatography recommended by FDA, USA
The extract of Celestrus paniculatus oil is an oil extract. The extract of Becoppa monnieri for use in the composition is either prepared by any known process or by refluxing an alcoholic extract of Becoppa monnieri, concentrating to a solid content of about 50-70% and drying the refluxed material at temperature about 50-90°C under vacuum, treating the dried material with organic solvent preferably chloroform for removal of the soluble fraction and then subjecting the insoluble fraction to refining to obtain a debitterized rich fraction of glycosides.
The said composition is in a powder, tablet, capsule, syrup or in suspension form and also is delivered through any other known carriers such as biscuits/snacks.
In case of composition in the form of tablets, capsules or powder form the Celestrus paniculatus oil is first adsorbed in Aerosil or any other suitable known adsorbing media and used accordingly.
It is generally believed that the Nootropic components present in the composition improves short term memory, long term memory and attention span, by exerting its effect on increasing concentration ability, increasing memory span, improving learning ability and overall mental performance. Reference is now made to the presence of Centella asiatica for psychotropic effects in the composition, which is responsible for improving the memory facets such as short term, long term memory and concentration ability. It is known that Becoppa monnieri effectively improves such facets and accordingly it is believed that the presence of Centella asiatica is complimentary to that of Becoppa monnieri in improving such mental facets. As both Centella asiatica and Becoppa monnieri are complimentary to each other, the activity of each of such constituents when present in combination has been ascertained and tests have shown that better levels of enhancement of memory facets are obtained where both the constituents are present in the composition. The nootropic & psychotropic properties are achieved. Simultaneously and depending upon the degree of enhancement required of such facets only one of such constituent may be used. Accordingly, and in accordance with one embodiment of this invention, the composition includes only Becoppa monnieri. In accordance with another embodiment and wherein higher all round levels of enhancement of memory is required, the composition contains both Becoppa monnieri and Centella asiatica.
The extract of Shatparvika comprises Acorus calamus and should have glycosides present in the range of about 35 to 65%. Preferably, but without implying any limitation to the scope of the invention, about 40-55% of glycosides is present in the Acorus calamus. Further, β-asarone present in Acorus calamus should not exceed to more than 5 ppm. Acorus calamus is responsible for recall and expression of the stored information from the brain. The extract is hydro-alcoholic extract of the Rhizome of the herb Acorus calamus and the extraction technique is adopted to either eliminate the β- asarone for obtaining extract of Acorus calamus or with β-asarone <5 ppm. The contents of β-asarone in the extract is measured by gas chromatography recommended by FDA, USA. Reference is now made to the presence of Shatparvika or Acorus calamus in the composition. As described herein above, the function of Shatparvika is to improve the recall and expression properties. However, the composition need not contain Shatparvika in the instance where such properties are not required. The extract of Vadangul used in the present invention comprises
Celestrus paniculatus oil extract.
To every 10 ml. of the composition in syrup form, the composition contains about 100-500 mg of Becoppa monnieri and preferably between 150- 300 mg. If less than 150 mg is present the efficacy of the composition is adversely affected, and desired results can not be obtained. If the composition contains more than 300 mg no additional activity is achieved. In fact, if the composition contains excessively high amount of Becoppa monnieri, such as more than 2000 mg the gastric irritation has been observed.
To every 10 ml of the composition, about 10-500 mg of Centella asiatica is present. Preferably, the composition contains about 25-200 mg of Centella asiatica. Such a composition also contains about 7.5 - 25 mg of Acorus calamus and preferably about 8.0 to 20 mg. The composition contains about 0.02 to 0.20 ml and preferably about 0.04 to 0.15 ml of Celestrus paniculatus oil.
The composition may be in a powder, tablet, capsule, syrup or suspension form. Preferably, an alcoholic or hydro-alcoholic extract of Becoppa monnieri prepared by the process of the present invention and as described subsequently herein is employed in the composition, as the bitter constituents are removed therefrom. A particular and advantageous . application is with respect to a syrup form, as a bitter palatable taste ought to be avoided. Even in the instance of the composition being in a powder or tablet form, it is preferred that the hydro-alcoholic extract of Becoppa monnieri of the process of the present invention is used in the composition.
However, as a bitter palatable taste may still be tolerated in a powder, capsule and tablet form, the known extract of Becoppa monnieri and Centella asiatica with the adequate concentration of active components may also be employed.
As desired, herein above, it is known to obtain a hydro hydro-alcoholic or alcoholic extract of Becoppa monnieri and Centella asiatica. Though each of the aforesaid extracts do contain glycosides in accordance with the present invention the starting material comprises an alcoholic extract of Becoppa monnieri and Centella asiatica, which is refluxed till the herb is exhausted and so as to obtain an extract having glycosides and other compounds certain of which are bitter and undesirable constituents.
The refluxed material is concentrated to have a solid content of about 50-70% under vacuum conditions and that the operating temperature is between 50-70°C. The concentrated product is dried at a temperature of about 50-90°C. It has been found that if higher temperature is employed it would then destroy or change the nature of palatable and active glycosides contained in the extract. The step of drying may be effected in a drum or tray dryer under vacuum at a temperature of about 50 to 90°C,and preferably about 50- 70°C so as to prevent any thermal damage to the palatable glycosides and to obtain a powdered form of the extract. Alternatively, the step of spraying drying may be effected in a spray dryer. The step of drying is carried out for a period of about 40 to 120 sees and preferably for a period of about 60 to 80 sec. If the step of drying is effected in a tray or drum dryer, the step of milling them follows the step of drying. In the instance of spray drying, the operating temperature should preferably be between 70 to 80°C.
The dried extract is subjected to the step of solubilising in solvents namely chloroform. The extracts are soluble in other solvents rather than chloroform, which are preferably not employed, as certain of the bitter constituents present in the extract are also soluble in such other solvents. Thus the step of solubilising is preferably carried out in chloroform as a solvent under atmospheric condition to obtain a soluble fraction and an insoluble fraction. The soluble fraction is rejected and such a process may be repeated for refinement of the insoluble fraction. The insoluble fraction is filtered and concentrated at about 50-70°C under vacuum and then dried also at a temperature not exceeding 70°C.
The dried powder is subjected to the step of refinement, which comprises in a first step of dissolving the said powder in water to obtain a soluble fraction. The soluble fraction is filtered and concentrated to about 50- 70% solids under vacuum.
Preferably, the step of refining consists in a second step and wherein the concentrated solids obtained from the first step of refining is dissolved in alcohol to obtain an alcohol soluble fraction and a second insoluble fraction. The alcohol soluble fraction is concentrated under vacuum at a temperature of about 50-70°C to obtain a concentrated powder to about 50-70% solid of content.
The step of refinement comprises in a third step, wherein the alcohol soluble fraction is dissolved in acetone to obtain a first fraction containing acetone soluble material and a second fraction insoluble in acetone and comprising debitterized glycocidic rich fraction, which is also subjected to the step of concentration and then finally dried at a temperature of about 50 to 70°C. The step of drying may be effected after each step of refinement or only after the third step of refinement.
The invention will now be described with reference to the following examples. EXAMPLE I:
A 10 ml composition in the form of syrup contained the following active ingredients: about 120 mg of the alcoholic extract of Becoppa monnieri about 15 mg of extract of Centella asiatica, about 15 mg of β-asarone free extract of Acorus calamus, about 0.03 ml of extracted oil of Celestrus paniculatus oil and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
Dosage:
Children upto 5 years about 5 ml - two times a day Children above 5 years including adults about 10 ml - 2 times a day
Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor.
The investigation showed perceptible beneficial effect but of a lower degree in mild cases of mental deficiency.
Attention span, short and long term memory and overall mental performance showed significant improvement, comparatively of lower magnitude) p < 0.05), when compared with the placebo treated group. p = statistical degree of significance. EXAMPLE H:
A 10 ml composition in the form of syrup contained the following active ingredients: about 250 mg of the alcoholic extract of Becoppa monnieri about 40 mg of extract of Centella asiatica, - about 22 mg of β-asarone free extract of Acorus calamus, about 0.15 ml of extracted oil of Celestrus paniculatus oil and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents. Dosage:
Children upto 5 years about 5 ml - two times a day
Children above 5 years including adults about 10 ml - 2 times a day
Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor. A considerable improvement was noted on the parameters under investigation (pO.OOl) on comparison with placebo as well as with example I When the results of both the serials was compared along with placebo it was observed that optimal results could be obtained by the doses given in example II. Statistically the results were highly significant in example Ilnd dosages. EXAMPLE πi:
A 10 ml composition in the form of syrup contained the following active ingredients: - about 250 mg of the alcoholic extract of Becoppa monnieri about 40 mg of extract of Centella asiatica, about 22 mg of β-asarone free extract of Acorus calamus, and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents. Dosage:
Children upto 5 years about 5 ml - two times a day
Children above 5 years including adults : about 10 ml - 2 times a day
Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor.
A considerable improvement was noted on the parameters under investigation (pO.OOl) on comparison with placebo as well as with example I When the results of both the serials was compared along with placebo it was observed that optimal results could be obtained by the doses given in example III.
Statistically the results were highly significant in example III dosages. EXAMPLE TV:
A 10 ml composition in the form of syrup contained the following active ingredients: - about 200 mg of the alcoholic extract of Becoppa monnieri about 25 mg of β-asarone free extract of Acorus calamus, about 0.10 ml of extracted oil of Celestrus paniculatus oil and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents. Dosage: Children upto 5 years about 5 ml - two times a day
Children above 5 years including adults about 10 ml - 2 times a day
Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor.
The composition exhibited marked improvement in nootropic properties. However, the degree of improvement was lesser than composition II. In the absence of Centella asiatica no psychotropic activity could be identified.
However, the composition was beneficial for short term, long term and improvement in the attention span. The degree of significance noted was p<0.02.
EXAMPLE V:
A 10 ml composition in the form of syrup contained the following active ingredients: about 200 mg of the alcoholic extract of Becoppa monnieri . - about 25 mg of β-asarone free extract of Acorus calamus, and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents. Dosage: Children upto 5 years about 5 ml - two times a day
Children above 5 years including adults about 10 ml - 2 times a day
Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor. The composition exhibited marked improvement in nootropic properties. However, the degree of improvement was lesser than composition II. In the absence of Centella asiatica no psychotropic activity could be identified. However, the composition was beneficial for short term, long term and improvement in the attention span.
The improvements in the recall and speech mechanism were significant.
The degree of significance noted was p<0.02. EXAMPLE VI:
A 10 ml composition in the form of syrup contained the following active ingredients: about 200 mg of extract of Centella asiatica, about 25 mg of β-asarone free extract of Acorus calamus, - about 0.10 ml of extracted oil of Celestrus paniculatus oil and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents. Dosage: Children upto 5 years about 5 ml - two times a day
Children above 5 years including adults : about 10 ml - 2 times a day
Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor.
This composition was tried without Becoppa monnieri and it was noticed that psychotropic properties were dominant, which resulted in improvements in hyper activity and therefore improvement in the α-activity of EEG was noticed. The improvements in the recall and speech mechanism were significant. EXAMPLE VII:
10 ml composition in the form of syrup contained the following active ingredients: about 200 mg of the alcoholic extract of Centella asiatica - about 25 mg of β-asarone free extract of Acorus calamus and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents. Dosage: Children upto 5 years about 5 ml - two times a day
Children above 5 years including adults : about 10 ml - 2 times a day Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor.
This composition was tried without Becoppa monnieri and it was noticed that psychotropic properties were dominant, which resulted in improvements in hyper activity and therefore improvement in the α-activity of EEG was noticed. The improvements in the recall and speech mechanism were significant. EXAMPLE VDT: 10 ml composition in the form of syrup contained the following active ingredients: about 200 mg of the alcoholic extract of Becoppa monnieri about 40 mg of extract of Centella asiatica, about 0.10 ml of extracted oil of Celestrus paniculatus oil and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
Dosage:
Children upto 5 years about 5 ml - two times a day . Children above 5 years including adults about 10 ml - 2 times a day
Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor.
The above composition was tried without the incorporation of Acorus calamus. After 3 months of therapy, significant increase in nootropic and pyschotropic properties were noticed. It was noticed that the recall mechanism was of lower significance as compared to composition I. EXAMPLE TX:
A 10 ml composition in the form of syrup contained the following active ingredients: about 200 mg of the alcoholic extract of Becoppa monnieri about 0.15 ml of extracted oil of Celestrus peniculatus and the balance amount is from known additives selected from stabilizers, aϊϊti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents. Dosage:
Children upto 5 years about 5 ml - two times a day
Children above 5 years including adults about 10 ml - 2 times a day
Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor.
When the Becoppa monnieri and Celestrus paniculatus oil were only administered, a significant nootropic was noticed in almost all the cases. The effect of hyper activity was minimum and the recall mechanism was also less. EXAMPLE X: A 10 ml composition in the form of syrup contained the following active ingredients: about 200 mg of extract of Centella asiatica, about 0.15 ml of extracted oil of Celestrus peniculatus and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents. Dosage: Children upto 5 years about 5 ml - two times a day
Children above 5 years including adults about 10 ml - 2 times a day
Dosages can be increased depending upon the severity of the disease or as prescribed by the doctor.
A significant pyschotropic property was notices after continuous oral administration of the above composition. There was also improvement in the hyper activity but there was a minimum effect on recall mechanism. EXAMPLE XI:
The brahmi herb (Becoppa monnieri / Centella asiatica) as a complete plant was dried and extracted with absolute Ethanol in a Stainless Steel Pan. Four parts of Ethanol was mixed with one part of Herb and the material refluxed for about 10-12 hours. The process was repeated about 6 times till the herb is exhausted. All the above 6 extractions were concentrated to a paste of about 80% solids. This was done under vacuum and the solvents were recovered. The material was dried under reduced pressure at a temperature of about 50°C in a vacuum drum drier. The powder obtained was extracted with pure chloroform (6 times) to remove the alkalides and oils. Identity test for alkaloids was performed. The material was filtered and chloroform insoluble fraction was concentrated to about 70% solids. The residue was dried in a vacuum drum drier. The dried powder was dissolved in about 6 times the quantity of distilled water and filtered. The supernatant was reduced to about 80% solids under vacuum and dissolved in pure Ethyl alcohol. The alcohol soluble fraction was reduced to about 80% solids under vacuum and dissolved in about 4 times the quantity of acetone. The acetone insoluble fraction was dried in drum drier. The dried powder was glycocidal rich fraction and debitterized extract of Brahmi herb. Identity test and quantitative analysis of saponins (Tritrepenic glycocides) was conducted. This fraction had saponin content of above about 15% to 20%.
In case of tablets, capsules or powder form, the Celestrus paniculatus oil is first adsorbed in Aerosil or any other suitable known adsorbing media and used accordingly.
If the composition is in the form of biscuits or snacks, each unit should contain the active ingredients as specified in the aforesaid examples.
Composition described and claimed is based on the herbal extracts in powder form and in the case Celestrus paniculatis in oil form. However, if the composition is made in liquid form, the extract described can also be used in paste / liquid form and the quantities calculated on the dry matter content corresponding to above composition.
Celestrus paniculatus oil is brought into water soluble phase by using Tween-20 or any such known emulsifying agent.
Conversion from ml. to mg.: l ml. x 0.93 = 0.93 gm 0.93 gm x 1000 = 930 mg INDUSTRIAL APPLICATION The composition described above is useful for treating the diseases which cause the mental incapabilities such as lower cholinergic activity, lower level of protein synthesis, presence of higher level of catechaliamine, improper functioning of 5 FIT in the brain, lower I.Q. level i.e. 70-50 and mental retardation caused by the following factors: - health of mother genetic disease; chromosomal diseases; maternal illness; anemia; - cardio-pulmonary diseases; hemorrhage and hypertension; malnutrition and the like.

Claims

We c|a πι:
1. A highly potent herbal composition for improving overall mental performance in children, adults and mentally deficient people characterized by using extracted active plant materials from Brahmi herb and at least one of the herbs from Acorus calamus and Celestrus paniculatus oil.
2. A highly potent herbal composition for improving overall mental performance in children, adults and mentally deficient people in 10ml/ 1 lgms characterized by using extracted active plant materials from Brahmi herb and a least one of the herbs from Acorus calamus and Celestrus paniculatus oil in the amounts as given below:
Brahmi herb - about 100-500 mg
Acorus calamus - about 7.5-35 mg
Celestrus paniculatus oil - about 0.02-0.2 ml and the balance amount , if any, is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
3. A herbal composition as claimed in claim 1 or 2 wherein the herbal extracts are in the form of a powder, liquid or paste and the quantities used are based on dry powder as give╬╖ in the composition.
4. A herbal composition as claimed in claim 1 or 2 wherein Brahmi herb extract is either obtained frpm Becoppa monnieri or from Centella asiatica or from combination of both.
5. A herbal composition as claimed in claim 4 wherein the preferred range of the following herbal material is as follows: Becoppa monnieri - about 150-300 mg
Centella asiatica - about 25-200 mg
Acorus calamus - about 8-20 mg
Celestrus paniculatus oil - about 0.04-0.15 ml
6. A herbal composition as claimed in claim 4 wherein the Becoppa monnieri and Centella asiatica used in the composition has preferably saponins content about 15-25%.
7. A herbal composition as claimed in claims 1 or 2 wherein the Acorus calamus used has preferably about 40-55% glycosides and ╬▓-asarone content below 5 ppm.
8. A herbal composition as claimed in claim 4 wherein Becoppa monnieri extract is an hydro-alcoholic extract.
9. A herbal composition as claimed in claim 4 wherein said Centella asiatica extract is an hydro-alcoholic extract.
10. A herbal composition as claimed in claims 1 or 2 & 7 wherein said Acorus calamus extract is hydro-alcoholic extract of the Rhizone of the herb and the extraction technique is adopted to either eliminate the ╬▓-asarone for obtaining extract of Acorus calamus or with ╬▓-asarone less than 5 ppm and the contents of ╬▓-asarone in the extract is measured by gas chromatography recommended by FDA, USA
11. A herbal composition as claimed in claims 1 or 2 & 9 wherein the extract of Celestrus paniculatus oil is an oil.
12. A herbal composition as claimed in claims 4 & 8 wherein the extract of Becoppa monnieri for use in the composition is either prepared by any known process or by refluxing an alcoholic extract of Becoppa monnieri, concentrating to a solid content of about 50-70% and drying the refluxed material at temperature about 50-90┬░C under vacuum, treating the dried material with organic solvent preferably chloroform for removal of the soluble fraction and then subjecting the insoluble fraction to refining to obtain a debitterized rich fraction of glycosides.
13. A herbal composition as claimed in preceding claims wherein the said composition is in a powder, tablet, capsule, syrup or in suspension form and also is delivered through any other known carriers such as biscuits/snacks.
14. A herbal composition as claimed in preceding claims wherein in 10 ml composition in syrup form contains the following active ingredients: about 120 mg of the alcoholic extract of Becoppa monnieri about 15 mg of extract of Centella asiatica, about 15 mg of ╬▓-asarone free extract of Acorus calamus, about 0.03 ml of extracted oil of Celestrus paniculatus oil and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
15. A herbal composition as claimed in preceding claims wherein 10 ml composition in syrup form contains the following active ingredients: - about 250 mg of the alcoholic extract of Becoppa monnieri about 40 mg of extract of Centella asiatica, about 22 mg of ╬▓-asarone free extract of Acorus calamus, about 0.15 ml of extracted oil of Celestrus paniculatus oil and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
16. A herbal composition as claimed in preceding claims wherein 10 ml composition in syrup form contains the following active ingredients: about 250 mg of the alcoholic extract of Becoppa monnieri - about 40 mg of extract of Centella asiatica, about 22 mg of ╬▓-asarone free extract of Acorus calamus, and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
17. A herbal composition as claimed in preceding claims wherein 10 ml composition in syrup form contains the following active ingredients: about 200 mg of the alcoholic extract of Becoppa monnieri about 25 mg of ╬▓-asarone free extract of Acorus calamus, about 0.10 ml of extracted oil of Celestrus paniculatus oil and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
18. A herbal composition as claimed in preceding claims wherein 10 ml composition in syrup form contains the following active ingredients: about 200 mg of the alcoholic extract of Becoppa monnieri - about 25 mg of ╬▓-asarone free extract of Acorus calamus, and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
19. A herbal composition as claimed in preceding claims wherein 10 ml composition in syrup form contains the following active ingredients: about 200 mg of extract of Centella asiatica, about 25 mg of ╬▓-asarone free extract of Acorus calamus, about 0.10 ml of extracted oil of Celestrus paniculatus oil and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
20. A herbal composition as claimed in preceding claims wherein 10 ml composition in syrup form contains the following active ingredients: about 200 mg of the alcoholic extract of Centella asiatica about 25 mg of ╬▓-asarone free extract of Acorus calamus and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
21. A herbal composition as claimed in preceding claims wherein 10 ml composition in syrup form contains the following active ingredients: - about 200 mg of the alcoholic extract of Becoppa monnieri about 40 mg of extract of Centella asiatica, about 0.10 ml of extracted oil of Celestrus paniculatus oil and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
22. A herbal composition as claimed in preceding claims wherein 10 ml composition in syrup form contains the following active ingredients: about 200 mg of the alcoholic extract of Becoppa monnieri about 0.15 ml of extracted oil of Celestrus paniculatus oil and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
23. A herbal composition as claimed in preceding claims wherein 10 ml composition in syrup form contains the following active ingredients: - about 200 mg of extract of Centella asiatica, about 0.15 ml of extracted oil of Celestrus paniculatus oil and the balance amount is from known additives selected from stabilizers, anti-caking agents, flavoring agents, sweetening agents, thickening agents, preservatives and coloring agents.
24. A herbal composition as claimed in claims 1 or 2 wherein in case of composition in the form of tablets, capsules or powder form the Celestrus paniculatus oil is first adsorbed in Aerosil or any other suitable known adsorbing media and used accordingly.
25. A method for improving the mental ability of a mammal comprising administering an effective amount of the composition of claims 1 or 2.
26. The method of claim 25 wherein the mammal is a human.
EP99940453A 1998-09-07 1999-08-09 Composition for improving mental capabilities in mammals Withdrawn EP1039919A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
INDE266098 1998-09-07
IN2658DE1998 1998-09-07
INDE265898 1998-09-07
IN2660DE1998 1998-09-07
INDE014699 1999-01-25
IN146DE1999 IN191484B (en) 1999-01-25 1999-01-25
INDE022299 1999-02-10
IN220DE1999 IN191695B (en) 1999-02-10 1999-02-10
INDE022099 1999-02-10
IN221DE1999 1999-02-10
IN222DE1999 1999-02-10
INDE022199 1999-02-10
PCT/IN1999/000036 WO2000013696A1 (en) 1998-09-07 1999-08-09 Composition for improving mental capabilities in mammals

Publications (1)

Publication Number Publication Date
EP1039919A1 true EP1039919A1 (en) 2000-10-04

Family

ID=27547440

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99940453A Withdrawn EP1039919A1 (en) 1998-09-07 1999-08-09 Composition for improving mental capabilities in mammals

Country Status (6)

Country Link
EP (1) EP1039919A1 (en)
JP (1) JP2002524419A (en)
CN (1) CN1277555A (en)
AU (1) AU742556B2 (en)
CA (1) CA2306165A1 (en)
WO (1) WO2000013696A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002003813A1 (en) * 2000-07-12 2002-01-17 Raj Kumar, Sujatha Use of dammarane-type triterpenoid saponins
WO2002003996A1 (en) * 2000-07-12 2002-01-17 RAJKUMAR, Sujatha Use of dammarane-type tritepenoid saporins
AU2002246308A1 (en) * 2002-02-14 2003-09-04 Dalmia Centre For Research And Development Herbal formulation for treating attention defienciency disorder (add/adht) and process for preparation
AU2003298474A1 (en) * 2003-12-26 2005-08-12 Council Of Scientific And Industrial Research Herbal formualtion containing centella asiatica and sesamum indicum as brain tonic
CN1303098C (en) * 2004-12-09 2007-03-07 中国人民解放军第二军医大学 Pseudo portulaca oleracea saponin compound, total sapon in and its application in medicine
CN1833692B (en) * 2005-03-15 2010-08-11 成都华高药业有限公司 False portulaca oleracea extracts, its prepn. and usage
DE102006033321A1 (en) * 2006-07-17 2008-01-24 Westfälische Wilhelms-Universität Münster Medical use of N-phenylpropenoyl amino acid derivatives and related compounds
CN103393733A (en) * 2013-08-19 2013-11-20 广西中医药大学 Centella asiatica (l.) urban effective fraction and application thereof
SG10201507607RA (en) * 2015-09-14 2017-04-27 Moleac Pte Ltd Process For Producing Traditional Chinese Medicine Compositions, And Compositions Obtainable By The Process
DE102021200826A1 (en) * 2021-01-29 2022-08-04 Eva Süßmann composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2972807B2 (en) * 1989-07-27 1999-11-08 トレードウインド株式会社 Anti-aging food and method for producing the same
IN179810B (en) * 1996-06-20 1997-12-13 Raptakos Brett & Co Ltd

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0013696A1 *

Also Published As

Publication number Publication date
AU742556B2 (en) 2002-01-03
AU5442599A (en) 2000-03-27
JP2002524419A (en) 2002-08-06
CA2306165A1 (en) 2000-03-16
CN1277555A (en) 2000-12-20
WO2000013696A1 (en) 2000-03-16

Similar Documents

Publication Publication Date Title
US4966893A (en) Method for treatment of senile dementia
EP2057994A1 (en) Prickly pear extract preparation
KR100382564B1 (en) Herbal composition for prevention and treatment of alzheimer&#39;s disease
AU742556B2 (en) Composition for improving mental capabilities in mammals
EP0370284B1 (en) A composition containing an extract obtained by a watercontaining organic solvent, and a process for preparing the same
US7514104B2 (en) Composition containing an extract of pericarpium zanthoxyli for protecting brain cells and improving memory
KR100450021B1 (en) Extracts of ginkgo biloba leaves with reduced 4′­o­methylpyridoxine and bioflavones content
JP3968405B2 (en) Antiallergic agent
JPH07274894A (en) Food/beverage for preventing gastric ulcer
JP5721353B2 (en) Bile acid secretion promoter
JP3334725B2 (en) Accelerator for reducing alcohol in the body, its metabolites and oral freshener
KR101082938B1 (en) Vitamin agent composition comprising enrichmented water-soluble vitamins and method for preparing thereof
KR101049493B1 (en) Compositions for improving memory power and learning ability comprising extract from lepidium apefalum as active ingredient
US5501866A (en) Product and method for inhibiting caffeine stimulation with theanine
KR101043212B1 (en) A food for improving brain function
US20030157201A1 (en) Composition for improving mental capabilities in mammals
US6159986A (en) Compounds and therapy for resisting memory loss in humans
KR100512912B1 (en) Alcohol metabolism herbal medicine accelerator
KR20150093141A (en) Composition for preventing or treating brain disease or neural disease comprising oriental herbal extracts
KR20120029992A (en) Compositions for improving memory power and learning ability comprising extract from artemisia apiaceae as active ingredient
US20190030087A1 (en) Composition Comprising an Extract of Liriopsis Tuber for Protecting Brain Cells and Improving Memory
KR100500029B1 (en) Crude drug composition for promoting memory which contains Rehmanniae radix preparata extract
KR20020074905A (en) Constituents for herbal healthy food containing radish extracts
JP2776927B2 (en) Brain function improver
US7083811B2 (en) Herbal composition for the prevention and treatment of dementia

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17P Request for examination filed

Effective date: 20000907

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MURALI, PANCHAPAGESA MUTHUSWAMY, DR.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DUBEY, GOVIND PRASHAD

Inventor name: PANDITA, MAHARAJ KRISHEN

17Q First examination report despatched

Effective date: 20020207

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 25/28 B

Ipc: 7A 61K 35/78 A

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031002